« Back
FuGENE SI: A novel and efficient siRNA transfection reagent with minimal cellular toxicity.
Poster Title: FuGENE SI: A novel and efficient siRNA transfection reagent with minimal cellular toxicity.
Submitted on 02 Jul 2021
Author(s): Tony Larsen, Douglas Grunwald, Chris Sherrill, and James Prudent
Affiliations: FuGENE Transfection (Fugent LLC)
Poster Views: 342
View poster »

Poster Information
Abstract: FuGENE® SI provides researchers the following benefits when compared to other siRNA transfection reagents available:

-Improved gene silencing with lower siRNA amounts
-Decreased cellular toxicity
-Usage across a wide range of routine and difficult-to-transfect cell lines
-Quick and easy protocol
-Ability to co-transfect DNA
-Lower Costs

To demonstrate the utility and benefits of utilizing FuGENE® SI we present to you the following:

-Flexible and Rapid Transfection Protocol with FuGENE®SI: Allows researchers to seed cells and transfect the same day, perfect for high-throughput screening (HTS) applications
-FuGENE® SI Transfection reagent allows for highly efficient uptake of fluorescently labeled siRNAs
-Robust and gentle knockdown of overexpressed, green florescent protein in eukaryotic cell lines with minimal amounts of siRNAs delivered by FuGENE®SI
-Improved knockdown performance of FuGENE®SI vs. competitor reagent RNAiMax®in human breast cancer cell line
-Knockdown of endogenous FXYD1 in A549 with FuGENE® SI increases cell survival after treatment with antibody/drug conjugate (FXYD1/Cardiac Glycoside)
Summary: FuGENE SI is a novel, high-efficiency, non-toxic transfection reagent engineered for delivery of siRNA, miRNA, and other short RNAs into biologically relevant human and animal cells.Report abuse »
Ask the author a question about this poster.
Ask a Question »

Creative Commons

Related Posters

Crosslinking & Label Transfer Protein Interaction Analysis
Creative Proteomics

Introduction to Circular Dichroism
Creative Proteomics

What NMR can do in the biopharmaceutical industry?—Creative Proteomics
Creative Proteomics

A streamlined workflow for the quality control, interpretation and analysis of timsTOF Pro data: towards large-scale proteomics
Chengpin Shen1, Xianming Liu2, Xiaoxian Du2, Xiaoqing Wang1, Hebin Liu1 and Ruoyu Wu2 1 Omicsolution Co., Ltd, Shanghai, China 2 Bruker Daltonics, Shanghai, China

CCS-centric protein identification using IM Score
Robin Park1, Patrick Garrett3, Sven Brehmer2, Titus Jung3, Vijayaraja Gnanasambandan1, Marc-Antoine Beauvais1, Sebastian Wehner2, Lennard Pfennig2, Hyunsoo Kim3, Christopher Adams1, Dennis Trede2, John R. Yates, III3, Rohan Thakur1 1Bruker Daltonics Inc., USA 2Bruker Daltonik GmbH, Bremen, Germany 3Scripps Research, San Diego, USA